SG11201701423RA - Compound targeting il-23a and tnf-alpha and uses thereof - Google Patents
Compound targeting il-23a and tnf-alpha and uses thereofInfo
- Publication number
- SG11201701423RA SG11201701423RA SG11201701423RA SG11201701423RA SG11201701423RA SG 11201701423R A SG11201701423R A SG 11201701423RA SG 11201701423R A SG11201701423R A SG 11201701423RA SG 11201701423R A SG11201701423R A SG 11201701423RA SG 11201701423R A SG11201701423R A SG 11201701423RA
- Authority
- SG
- Singapore
- Prior art keywords
- tnf
- alpha
- compound targeting
- targeting
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P15/00—Preparation of compounds containing at least three condensed carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462045498P | 2014-09-03 | 2014-09-03 | |
PCT/US2015/048260 WO2016036918A1 (en) | 2014-09-03 | 2015-09-03 | Compound targeting il-23a and tnf-alpha and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701423RA true SG11201701423RA (en) | 2017-03-30 |
Family
ID=55401727
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912591RA SG10201912591RA (en) | 2014-09-03 | 2015-09-03 | Compound targeting il-23a and tnf-alpha and uses thereof |
SG11201701423RA SG11201701423RA (en) | 2014-09-03 | 2015-09-03 | Compound targeting il-23a and tnf-alpha and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912591RA SG10201912591RA (en) | 2014-09-03 | 2015-09-03 | Compound targeting il-23a and tnf-alpha and uses thereof |
Country Status (25)
Country | Link |
---|---|
US (4) | US10059763B2 (ru) |
EP (1) | EP3189153B1 (ru) |
JP (2) | JP6746564B2 (ru) |
KR (1) | KR102523914B1 (ru) |
CN (1) | CN107109456B (ru) |
AP (1) | AP2017009776A0 (ru) |
AR (1) | AR101753A1 (ru) |
AU (1) | AU2015311913B2 (ru) |
BR (1) | BR112017004169A2 (ru) |
CA (1) | CA2959629C (ru) |
CL (1) | CL2017000525A1 (ru) |
CO (1) | CO2017002253A2 (ru) |
EA (2) | EA202193002A2 (ru) |
ES (1) | ES2887549T3 (ru) |
IL (1) | IL250717B (ru) |
MX (2) | MX2017002765A (ru) |
MY (1) | MY192824A (ru) |
PE (1) | PE20171139A1 (ru) |
PH (1) | PH12017500370A1 (ru) |
SG (2) | SG10201912591RA (ru) |
TW (1) | TWI711629B (ru) |
UA (1) | UA123624C2 (ru) |
UY (1) | UY36287A (ru) |
WO (1) | WO2016036918A1 (ru) |
ZA (1) | ZA201701384B (ru) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
CN103282382B (zh) | 2010-11-04 | 2017-11-03 | 勃林格殷格翰国际有限公司 | 抗il‑23抗体 |
KR102124758B1 (ko) | 2012-05-03 | 2020-06-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-23p19 항체 |
JP2017524359A (ja) | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−23a関連疾患の処置に有用なバイオマーカー |
AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
TW202016151A (zh) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
CN111273019A (zh) * | 2018-12-04 | 2020-06-12 | 山东博安生物技术有限公司 | 一种杜拉鲁肽elisa检测方法 |
CA3144567A1 (en) | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
US20220242945A1 (en) * | 2019-06-21 | 2022-08-04 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
CA3201564A1 (en) * | 2020-12-09 | 2022-06-16 | Jung Min Yoo | Anti-ox40l antibody, anti-ox40l/anti-tnfalpha bispecific antibody, and uses thereof |
WO2024061288A1 (en) * | 2022-09-21 | 2024-03-28 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Antibodies targeting tnf alpha and il-23 and uses thereof |
Family Cites Families (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
JPH0825869B2 (ja) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
BRPI9715219B8 (pt) * | 1996-02-09 | 2015-07-07 | Abbvie Biotechnology Ltd | Vetor recombinante de expressão, e célula hospedeira procariótica. |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
ES2300113T3 (es) | 1996-08-02 | 2008-06-01 | Bristol-Myers Squibb Company | Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo. |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
CO4810232A1 (es) | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
AU2661199A (en) | 1998-02-06 | 1999-08-23 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
EP1072610B1 (en) | 1998-04-14 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Novel cytokine-like protein |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
AU5728999A (en) | 1998-07-28 | 2000-02-21 | Micromet Ag | Heterominibodies |
US6875741B2 (en) * | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ATE389019T1 (de) | 1999-09-09 | 2008-03-15 | Schering Corp | Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
JP5073909B2 (ja) | 2000-05-10 | 2012-11-14 | メルク・シャープ・アンド・ドーム・コーポレーション | 哺乳動物レセプタータンパク質;関連する試薬および方法 |
WO2002002781A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Heterodimeric fusion proteins |
UA81743C2 (ru) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ЧЕЛОВЕКА, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С ФАКТОРОМ НЕКРОЗА ОПУХОЛЕЙ АЛЬФА (ФНПα), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ РЕВМАТОИДНОГО АРТРИТА |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
EP1449431A4 (en) | 2001-10-24 | 2007-11-28 | Chugai Pharmaceutical Co Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED SRGF ANIMAL |
ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
NZ539271A (en) | 2002-10-30 | 2008-12-24 | Genentech Inc | Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23) |
AU2003303384A1 (en) | 2002-12-23 | 2004-07-22 | Schering Corporation | Uses of mammalian cytokine; related reagents |
WO2004071517A2 (en) | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
CN1759123B (zh) | 2003-03-10 | 2011-04-13 | 先灵公司 | Il-23激动剂及拮抗剂的用途;相关试剂 |
WO2005005612A2 (en) | 2003-07-01 | 2005-01-20 | University Of Virginia Patent Foundation | Tag-1 and tag-2 proteins and uses thereof |
EP1682178B8 (en) | 2003-11-04 | 2010-09-01 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for cancers expressing the cd40 antigen |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
ATE533502T1 (de) | 2004-02-17 | 2011-12-15 | Schering Corp | Verfahren zur modulation der il-23-aktivität; relevante reagenzien |
BRPI0510617A (pt) | 2004-05-03 | 2007-10-30 | Schering Corp | uso de expressão de il-17 para prever inflamação de pele; processos de tratamento |
US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
JP2008503217A (ja) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
US20060084145A1 (en) | 2004-09-27 | 2006-04-20 | Anderson Glenn M | sRAGE mimetibody, compositions, methods and uses |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US7820168B2 (en) | 2004-12-20 | 2010-10-26 | Schering Corporation | Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17 |
CA2605024C (en) * | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP1896073B1 (en) | 2005-06-30 | 2013-03-06 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
EP1910414A4 (en) | 2005-06-30 | 2009-02-11 | Archemix Corp | POLYNUCLEOTIDES AND POLYPEPTIDES OF THE CYTOKINE IL-12 FAMILY |
MX2008002179A (es) | 2005-08-25 | 2008-04-22 | Lilly Co Eli | Anticuerpos anti-il-23. |
ES2619845T3 (es) | 2005-08-31 | 2017-06-27 | Merck Sharp & Dohme Corp. | Anticuerpos anti-IL-23 diseñados por ingeniería genética |
JP2009507023A (ja) | 2005-09-01 | 2009-02-19 | シェーリング コーポレイション | 自己免疫性眼炎症性疾患を処置するためのil−23およびil−17のアンタゴニストの使用 |
BRPI0620914A2 (pt) | 2005-12-28 | 2011-11-29 | Centocor Inc | marcadores e métodos para avaliar e tratar psorìase e distúrbios relacionados |
ES2517420T3 (es) | 2005-12-29 | 2014-11-03 | Janssen Biotech, Inc. | Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
BRPI0713133A2 (pt) | 2006-06-19 | 2012-03-27 | Wyeth Corp | métodos de modular il-22 e il-17 |
CN101600457B (zh) | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
US20080200655A1 (en) | 2007-02-16 | 2008-08-21 | Wyeth | Protein Formulations Containing Sorbitol |
CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
EP2056838B1 (en) * | 2007-02-28 | 2013-09-25 | Merck Sharp & Dohme Corp. | Combination therapy for treatment of immune disorders |
CN101821288A (zh) | 2007-06-21 | 2010-09-01 | 宏观基因有限公司 | 共价双抗体及其用途 |
US8871906B2 (en) | 2007-09-04 | 2014-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Deletions in domain II of pseudomonas exotoxin a that remove immunogenic epitopes |
AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
EP2212442A1 (en) | 2007-10-26 | 2010-08-04 | Galderma Research & Development | Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof |
CA2607771A1 (en) | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Humanized anti-venezuelan equine encephalitis virus recombinant antibody |
SG10201604258YA (en) | 2007-11-30 | 2016-07-28 | Abbvie Biotechnology Ltd | Anti-tnf antibody formulations |
WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
EP2245064B1 (en) * | 2007-12-21 | 2014-07-23 | Medimmune Limited | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha) |
US8563697B2 (en) | 2008-08-14 | 2013-10-22 | Cephalon Australia Pty. Ltd. | Anti-IL-12/IL-23 antibodies |
US8263748B2 (en) | 2008-08-27 | 2012-09-11 | Schering Corporation | Lyophilized formulations of engineered anti-IL-23p19 antibodies |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
KR101940059B1 (ko) | 2008-12-19 | 2019-01-18 | 마크로제닉스, 인크. | 공유결합형 디아바디 및 이의 용도 |
EP2414393A1 (en) | 2009-04-01 | 2012-02-08 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
EP2414546A4 (en) | 2009-04-02 | 2013-03-13 | Univ Johns Hopkins | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF CHRONIC INFLAMMATORY INTESTINAL DISEASES AND COLON CANCER |
WO2011011797A2 (en) | 2009-07-24 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine compositions and methods of use thereof |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
EP2504030A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP |
KR101791430B1 (ko) | 2009-11-30 | 2017-10-30 | 얀센 바이오테크 인코포레이티드 | 이펙터 기능이 제거된 항체 Fc 돌연변이체 |
US8257397B2 (en) | 2009-12-02 | 2012-09-04 | Spartek Medical, Inc. | Low profile spinal prosthesis incorporating a bone anchor having a deflectable post and a compound spinal rod |
MX354143B (es) | 2009-12-02 | 2018-02-14 | Imaginab Inc | Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso. |
GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
US8927693B2 (en) | 2010-02-18 | 2015-01-06 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind IL-23 |
ES2586579T3 (es) | 2010-02-19 | 2016-10-17 | Xencor, Inc. | Nuevas inmunoadhesinas de CTLA4-IG |
SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
WO2011109365A2 (en) | 2010-03-01 | 2011-09-09 | Progenics Pharmaceuticals, Inc. | Concentrated protein formulations and uses thereof |
US9072668B2 (en) * | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
CN103026229B (zh) | 2010-06-15 | 2016-03-30 | 细胞基因公司 | 用于治疗银屑病的生物标志物 |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
US9127057B2 (en) | 2010-07-20 | 2015-09-08 | Teva Pharmaceuticals Ausralia Pty Ltd | Anti-IL-23 heterodimer specific antibodies |
ES2667100T3 (es) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Diacuerpos covalentes y sus usos |
EP2640745B1 (en) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Bivalent and bispecific anti-il6/anti-il23 antibodies |
EP2635694A4 (en) | 2010-11-02 | 2015-11-11 | Abbott Lab | VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF |
CN103282382B (zh) | 2010-11-04 | 2017-11-03 | 勃林格殷格翰国际有限公司 | 抗il‑23抗体 |
WO2012083370A1 (en) * | 2010-12-22 | 2012-06-28 | Cephalon Australia Pty Ltd | Modified antibody with improved half-life |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
TW201309330A (zh) | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
AU2012259162C1 (en) | 2011-05-21 | 2020-05-21 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
ES2857734T3 (es) * | 2011-08-23 | 2021-09-29 | Roche Glycart Ag | Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas |
BR112014009810A2 (pt) | 2011-10-24 | 2017-04-25 | Abbvie Inc | imunoligantes biespecíficos dirigidos contra tnf e il-17 |
EP2776061B1 (en) | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
WO2013120929A1 (en) * | 2012-02-15 | 2013-08-22 | F. Hoffmann-La Roche Ag | Fc-receptor based affinity chromatography |
KR102124758B1 (ko) * | 2012-05-03 | 2020-06-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-23p19 항체 |
EP2866833B1 (en) | 2012-06-27 | 2019-05-15 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
US20140213772A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
CN105307675A (zh) | 2013-03-15 | 2016-02-03 | 美国安进公司 | 使用抗il23抗体治疗克罗恩氏病的方法 |
RU2015143833A (ru) | 2013-03-15 | 2017-04-21 | Эббви Инк. | СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα |
JP2016517408A (ja) | 2013-03-15 | 2016-06-16 | アムジェン インコーポレイテッド | 抗il−23抗体を用いた乾癬の治療方法 |
KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
EP3253794A1 (en) | 2015-02-04 | 2017-12-13 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
-
2015
- 2015-09-03 EA EA202193002A patent/EA202193002A2/ru unknown
- 2015-09-03 BR BR112017004169A patent/BR112017004169A2/pt active Search and Examination
- 2015-09-03 MY MYPI2017000309A patent/MY192824A/en unknown
- 2015-09-03 AU AU2015311913A patent/AU2015311913B2/en active Active
- 2015-09-03 SG SG10201912591RA patent/SG10201912591RA/en unknown
- 2015-09-03 CA CA2959629A patent/CA2959629C/en active Active
- 2015-09-03 MX MX2017002765A patent/MX2017002765A/es unknown
- 2015-09-03 EA EA201790505A patent/EA039598B9/ru unknown
- 2015-09-03 UA UAA201703065A patent/UA123624C2/uk unknown
- 2015-09-03 PE PE2017000401A patent/PE20171139A1/es unknown
- 2015-09-03 UY UY0001036287A patent/UY36287A/es active IP Right Grant
- 2015-09-03 US US14/844,338 patent/US10059763B2/en active Active
- 2015-09-03 CN CN201580057244.6A patent/CN107109456B/zh active Active
- 2015-09-03 KR KR1020177008883A patent/KR102523914B1/ko active IP Right Grant
- 2015-09-03 TW TW104129171A patent/TWI711629B/zh active
- 2015-09-03 ES ES15838895T patent/ES2887549T3/es active Active
- 2015-09-03 WO PCT/US2015/048260 patent/WO2016036918A1/en active Application Filing
- 2015-09-03 EP EP15838895.9A patent/EP3189153B1/en active Active
- 2015-09-03 SG SG11201701423RA patent/SG11201701423RA/en unknown
- 2015-09-03 AP AP2017009776A patent/AP2017009776A0/en unknown
- 2015-09-03 AR ARP150102820A patent/AR101753A1/es unknown
- 2015-09-03 JP JP2017512334A patent/JP6746564B2/ja active Active
-
2017
- 2017-02-22 IL IL250717A patent/IL250717B/en active IP Right Grant
- 2017-02-23 ZA ZA2017/01384A patent/ZA201701384B/en unknown
- 2017-02-28 PH PH12017500370A patent/PH12017500370A1/en unknown
- 2017-03-01 MX MX2021014663A patent/MX2021014663A/es unknown
- 2017-03-03 CL CL2017000525A patent/CL2017000525A1/es unknown
- 2017-03-07 CO CONC2017/0002253A patent/CO2017002253A2/es unknown
-
2018
- 2018-08-01 US US16/052,133 patent/US10793629B2/en active Active
-
2020
- 2020-04-17 JP JP2020073942A patent/JP7072600B2/ja active Active
- 2020-08-26 US US17/002,890 patent/US11680096B2/en active Active
-
2023
- 2023-03-06 US US18/178,783 patent/US20230382988A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243073A1 (zh) | 治療性化合物及其用途 | |
HK1231471A1 (zh) | -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途 | |
GB2530831B (en) | Targeted mutations | |
IL252216B (en) | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | |
IL250717B (en) | A23-il and TNF-alpha targeting compound and uses thereof | |
IL251512A0 (en) | Mist sprayer and its uses | |
PL3110483T3 (pl) | Inhalator | |
HUE044571T2 (hu) | Módosított ciklopentapeptidek és alkalmazásaik | |
ZA201701492B (en) | Pyrazolothiazole compound and medicine | |
GB201419650D0 (en) | Modified heterocyclase | |
AU358579S (en) | Inhaler | |
GB201400470D0 (en) | Body protection | |
PL2944740T3 (pl) | Układ i korpus łączący | |
GB201510123D0 (en) | Compounds and their uses | |
SG10201503358UA (en) | Corrector | |
GB201420001D0 (en) | Polyamide compounds and uses thereof | |
PT2923578T (pt) | Método para a produção de um produto alimentar | |
GB201407596D0 (en) | New compounds and uses | |
GB201407599D0 (en) | New compounds and uses | |
GB201414460D0 (en) | Herbicidal compounds and uses | |
GB201414456D0 (en) | Herbicidal compounds and uses | |
GB201414461D0 (en) | Herbicidal compounds and uses | |
GB201414455D0 (en) | Herbicidal compounds and uses | |
GB201414453D0 (en) | Herbicidal compounds and uses | |
GB201414459D0 (en) | Herbicidal compounds and uses |